Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F16-IL2 + doxorubicin
- Development stage
- Discontinued
- Lead developer
- Philogen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
F16-IL2 + doxorubicin is a combination therapy under clinical investigation for the treatment of advanced solid tumors and metastatic breast cancer. F16-IL2 is a recombinant fusion protein, known as an immunocytokine, composed of the antibody fragment F16—which targets the A1 domain of tenascin-C in tumor stroma—and human interleukin 2 (IL2). This design enables selective localization to tumor tissues and enhances immune-mediated antitumor activity. Doxorubicin is an anthracycline chemotherapeutic agent that works primarily by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cells. The combination aims to leverage both targeted immune activation via IL2 at the tumor site and direct cytotoxicity from doxorubicin. Clinical trials have shown this regimen can be safely administered with manageable toxicity profiles[5][4][3]. Philogen has been involved in developing F16-IL2[2].
- Brand names
- Adriamycin (for doxorubicin)
- Other names
- immunocytokine F16-IL2recombinant antibody-cytokine fusion protein (for F16-IL2)hydroxydaunorubicin (for doxorubicin)
02
Targets
DNATOP2A (DNA topoisomerase II)IL-2R (Interleukin-2/interleukin-15 receptor complex)TNC-A1 (Tenascin-C fibronectin type III-A1 domain)
Beyond the preview
Go deeper on F16-IL2 + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F16-IL2 + doxorubicin.